Dabigatran assessment in patients with acute complications using routine coagulation assays

2014 ◽  
Vol 25 (5) ◽  
pp. 426-434 ◽  
Author(s):  
Linda Stang ◽  
Susan Nahirniak ◽  
Ken Butcher ◽  
Artur J. Szkotak
Keyword(s):  
Coagulation Assays ◽  
Acute Complications ◽  
Routine Coagulation

scholarly journals Fibrin Clot Formation and Lysis in Plasma

2020 ◽  
Vol 3 (4) ◽  
pp. 67
Author(s):  
Julie Brogaard Larsen ◽  
Anne-Mette Hvas
Keyword(s):  
Fibrinolytic Activity ◽  
Research Laboratory ◽  
Ex Vivo ◽  
Fibrin Clot ◽  
Clot Formation ◽  
Coagulation Assays ◽  
Fibrin Formation ◽  
Over Time ◽  
Routine Coagulation

Disturbance in the balance between fibrin formation and fibrinolysis can lead to either bleeding or thrombosis; however, our current routine coagulation assays are not sensitive to altered fibrinolysis. The clot formation and lysis assay is a dynamic plasma-based analysis that assesses the patient’s capacity for fibrin formation and fibrinolysis by adding an activator of coagulation as well as fibrinolysis to plasma and measuring ex vivo fibrin clot formation and breakdown over time. This assay provides detailed information on the fibrinolytic activity but is currently used for research only, as the assay is prone to inter-laboratory variation and as it demands experienced laboratory technicians as well as specialized personnel to validate and interpret the results. Here, we describe a protocol for the clot formation and lysis assay used at our research laboratory.

scholarly journals Preanalytical Variables in Coagulation Testing: Setting the Stage for Accurate Results

2019 ◽  
Vol 45 (05) ◽  
pp. 433-448 ◽  
Author(s):  
Robert C. Gosselin ◽  
Richard A. Marlar
Keyword(s):  
Laboratory Practice ◽  
Coagulation Assays ◽  
Practice Recommendations ◽  
Specimen Collection ◽  
Coagulation Testing ◽  
Specimen Processing ◽  
Processing And Storage ◽  
And Storage ◽  
Routine Coagulation

AbstractMany preanalytical variables may affect the results of routine coagulation assays. While advances in laboratory instrumentation have partially addressed the laboratory's ability to recognize some of these variables, there remains an increased reliance on laboratory personnel to recognize the three potential areas where coagulation testing preanalytical issues may arise: (1) specimen collection (including patient selection), (2) specimen transportation and stability, and (3) specimen processing and storage. The purpose of this article is to identify the preanalytical variables associated with coagulation-related testing and provide laboratory practice recommendations in an effort to improve the quality of coagulation testing and accuracy of result reporting.

scholarly journals Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays

2014 ◽  
Vol 12 (9) ◽  
pp. 1545-1553 ◽  
Author(s):  
A. Hillarp ◽  
K. M. Gustafsson ◽  
L. Faxälv ◽  
K. Strandberg ◽  
F. Baghaei ◽  
...  
Keyword(s):  
Factor Xa ◽  
Factor Xa Inhibitor ◽  
Direct Factor ◽  
Coagulation Assays ◽  
Routine Coagulation

scholarly journals Influence of dabigatran and rivaroxaban on routine coagulation assays

2015 ◽  
Vol 113 (01) ◽  
pp. 154-164 ◽  
Author(s):  
Els Bailleul ◽  
Bernard Chatelain ◽  
Anne Demulder ◽  
Katrien Devreese ◽  
Jonathan Douxfils ◽  
...  
Keyword(s):  
External Quality Assessment ◽  
Nationwide Survey ◽  
Activated Partial Thromboplastin Time ◽  
Dependent Manner ◽  
Activity Assay ◽  
External Quality ◽  
External Quality Assessment Scheme ◽  
Coagulation Assays ◽  
Coagulation Testing ◽  
Routine Coagulation

SummaryThe Belgian national External Quality Assessment Scheme performed a nationwide survey using lyophilised plasma samples spiked with dabigatran or rivaroxaban to demonstrate to the Belgian clinical laboratories how these drugs affect their routine coagulation assays prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and antithrombin. Virtually all Belgian laboratories performing routine coagulation testing (189/192) participated in the survey. Both, dabigatran and rivaroxaban significantly prolonged the PT and aPTT in a concentration- and reagent-dependent manner. PT reagents were more influenced by rivaroxaban than by dabigatran and aPTT reagents more influenced by dabigatran than by rivaroxaban. Among PT reagents, Neoplastin R® was the most sensitive to rivaroxaban and Innovin ® and Thromborel S® the least sensitive. Converting PT results to INR only increased the variability between reagents. Among aPTT reagents, Actin FSL® was the least sensitive to dabigatran while the other aPTT reagents showed slightly higher sensitivities. The presence of dabigatran led to falsely reduced fibrinogen concentrations when measured with a low thrombin concentration reagent. The presence of dabigatran caused an overestimation of the antithrombin level when measured with a thrombin-based activity assay and the presence of rivaroxaban an overestimation of the antithrombin level when measured with a FXa-based assay. Instrument-related differences were found for all tested parameters. In conclusion, this paper provides detailed information on the effect of dabigatran and rivaroxaban on routine coagulation assays as performed with a large number of reagent/instrument combinations.

Autoverification of routine coagulation assays in a multi-center laboratory

2016 ◽  
Vol 76 (6) ◽  
pp. 500-502 ◽  
Author(s):  
Liselotte Onelöv ◽  
Elisabeth Gustafsson ◽  
Eva Grönlund ◽  
Helena Andersson ◽  
Gisela Hellberg ◽  
...  
Keyword(s):  
Coagulation Assays ◽  
Routine Coagulation
Sign in / Sign up

Export Citation Format

Share Document